Arkolith/Insider Trading/ENTA/Form 4

Rottinghaus Scott T.

Chief Medical OfficerENANTA PHARMACEUTICALS INC (ENTA) · full profile →Form 4 · filed Jul 15, 2024
Net Selling
Open-Market Buys
$0
Open-Market Sells
$191K
Net Open-Market Flow
-$191K
Transactions
5
4 non-derivative · 1 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Jul 15, 2024Sell(S)5K$17.08$92K22K
Jul 15, 2024Option exercise(M)5K$8.99$48K27K
Jul 12, 2024Sell(S)2K$15.04$34K22K
Jul 11, 2024Sell(S)4K$15.07$65K24K

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Jul 15, 2024Option exercise(M)5K—$081K

Transaction Codes

S
Open-market sale
M
Option exercise / conversion

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001062993-24-013820) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML

Keep exploring

Connected pages for ENANTA PHARMACEUTICALS INC

Build

Ask your agent about ENTA insider filings

This filing is the Follow view. The Build view lets your agent pull every Form 4 for the issuer, the net open-market picture over 90 days, and the accession behind each row, through REST or MCP.

Get a key Compare plansForm 4 data
Copy-paste
curl -H "Authorization: Bearer YOUR_API_KEY" \
  "https://arkolith.com/api/v1/filing/0001062993-24-013820"
Ask your agent
Use Arkolith to summarize insider buying and selling at ENANTA PHARMACEUTICALS INC
over the last 90 days and cite the filings.